These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 32827795)
1. Selective elimination of human pluripotent stem cells by Anti-Dsg2 antibody-doxorubicin conjugates. Park J; Lee NG; Oh M; Song J; Kim W; Kwon MG; Kim SG; Han BS; Bae KH; Lee DG; Lee SH; Park JG; Kim JH; Lee J; Min JK Biomaterials; 2020 Nov; 259():120265. PubMed ID: 32827795 [TBL] [Abstract][Full Text] [Related]
2. DSG2 Is a Functional Cell Surface Marker for Identification and Isolation of Human Pluripotent Stem Cells. Park J; Son Y; Lee NG; Lee K; Lee DG; Song J; Lee J; Kim S; Cho MJ; Jang JH; Lee J; Park JG; Kim YG; Kim JS; Lee J; Cho YS; Park YJ; Han BS; Bae KH; Han S; Kang B; Haam S; Lee SH; Lee SC; Min JK Stem Cell Reports; 2018 Jul; 11(1):115-127. PubMed ID: 29910125 [TBL] [Abstract][Full Text] [Related]
3. Photoactivable Elimination of Tumorigenic Human Induced Pluripotent Stem Cells by Using a Lectin-Doxorubicin Prodrug Conjugate. Dion J; Minoshima F; Saito S; Kiyoi K; Hasehira K; Tateno H Chembiochem; 2019 Jun; 20(12):1606-1611. PubMed ID: 30737871 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of pluripotent stem cell-derived teratoma formation by small molecules. Lee MO; Moon SH; Jeong HC; Yi JY; Lee TH; Shim SH; Rhee YH; Lee SH; Oh SJ; Lee MY; Han MJ; Cho YS; Chung HM; Kim KS; Cha HJ Proc Natl Acad Sci U S A; 2013 Aug; 110(35):E3281-90. PubMed ID: 23918355 [TBL] [Abstract][Full Text] [Related]
5. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck. Nan A; Ghandehari H; Hebert C; Siavash H; Nikitakis N; Reynolds M; Sauk JJ J Drug Target; 2005 Apr; 13(3):189-97. PubMed ID: 16036307 [TBL] [Abstract][Full Text] [Related]
6. In vivo surveillance and elimination of teratoma-forming human embryonic stem cells with monoclonal antibody 2448 targeting annexin A2. Tan HL; Tan BZ; Goh WXT; Cua S; Choo A Biotechnol Bioeng; 2019 Nov; 116(11):2996-3005. PubMed ID: 31388993 [TBL] [Abstract][Full Text] [Related]
8. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin. Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482 [TBL] [Abstract][Full Text] [Related]
9. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity. Ulbrich K; Etrych T; Chytil P; Jelínková M; Ríhová B J Control Release; 2003 Feb; 87(1-3):33-47. PubMed ID: 12618021 [TBL] [Abstract][Full Text] [Related]
10. Legumain-cleavable 4-arm poly(ethylene glycol)-doxorubicin conjugate for tumor specific delivery and release. Zhou H; Sun H; Lv S; Zhang D; Zhang X; Tang Z; Chen X Acta Biomater; 2017 May; 54():227-238. PubMed ID: 28315495 [TBL] [Abstract][Full Text] [Related]
11. Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates. Lidický O; Janoušková O; Strohalm J; Alam M; Klener P; Etrych T Molecules; 2015 Nov; 20(11):19849-64. PubMed ID: 26556320 [TBL] [Abstract][Full Text] [Related]
12. Technical approaches to induce selective cell death of pluripotent stem cells. Jeong HC; Cho SJ; Lee MO; Cha HJ Cell Mol Life Sci; 2017 Jul; 74(14):2601-2611. PubMed ID: 28246701 [TBL] [Abstract][Full Text] [Related]
14. Conjugating doxorubicin to polymannose: a new strategy for target specific delivery to lung cancer cells. Francis AP; Jayakrishnan A J Biomater Sci Polym Ed; 2019 Nov; 30(16):1471-1488. PubMed ID: 31322972 [TBL] [Abstract][Full Text] [Related]
15. Tumor targeting using anti-her2 immunoliposomes. Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487 [TBL] [Abstract][Full Text] [Related]
16. A doxorubicin-CNGRC-peptide conjugate with prodrug properties. van Hensbergen Y; Broxterman HJ; Elderkamp YW; Lankelma J; Beers JC; Heijn M; Boven E; Hoekman K; Pinedo HM Biochem Pharmacol; 2002 Mar; 63(5):897-908. PubMed ID: 11911842 [TBL] [Abstract][Full Text] [Related]
17. Differentiation-Defective Human Induced Pluripotent Stem Cells Reveal Strengths and Limitations of the Teratoma Assay and In Vitro Pluripotency Assays. Bouma MJ; van Iterson M; Janssen B; Mummery CL; Salvatori DCF; Freund C Stem Cell Reports; 2017 May; 8(5):1340-1353. PubMed ID: 28494940 [TBL] [Abstract][Full Text] [Related]
18. Polymeric drugs based on conjugates of synthetic and natural macromolecules. II. Anti-cancer activity of antibody or (Fab')(2)-targeted conjugates and combined therapy with immunomodulators. Ríhová B; Jelínková M; Strohalm J; Subr V; Plocová D; Hovorka O; Novák M; Plundrová D; Germano Y; Ulbrich K J Control Release; 2000 Feb; 64(1-3):241-61. PubMed ID: 10640661 [TBL] [Abstract][Full Text] [Related]
19. Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin. Wahl AF; Donaldson KL; Mixan BJ; Trail PA; Siegall CB Int J Cancer; 2001 Aug; 93(4):590-600. PubMed ID: 11477565 [TBL] [Abstract][Full Text] [Related]
20. The Tumorigenic Potential of Human Pluripotent Stem Cells. Lezmi E; Benvenisty N Stem Cells Transl Med; 2022 Aug; 11(8):791-796. PubMed ID: 35679163 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]